Argatroban

Generic Name: Argatroban

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₆N_₆O_₅S

CAS Number: 74863-84-6

Unique Ingredient Identifier: OCY3U280Y3

Background: Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in ...

Indication: Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.

Associated Conditions: Thrombosis

Associated Therapies: -

Clinical Trials

Safety of Argatroban Infusion in Conduction Disturbances

Phase 4

Completed

Conditions: Stable Coronary Artery Disease (CAD)
Unstable Angina (Troponin Negative)

Interventions: Drug: Argatroban

First Posted Date: 2023-02-23

Last Posted Date: 2024-03-18

Lead Sponsor: Mitsubishi Tanabe Pharma GmbH

Target Recruit Count: 50

Registration Number: NCT05740371

Locations: 🇩🇪
Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg, Rotenburg an der Fulda, Hessen, Germany
🇩🇪
University Hospital Frankfurt, Frankfurt am Main, Hessen, Germany

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Phase 1

Completed

Conditions: Heparin-induced Thrombocytopenia

Interventions: Drug: VLX-1005
Drug: Argatroban

First Posted Date: 2022-04-13

Last Posted Date: 2023-01-11

Lead Sponsor: Veralox Therapeutics

Target Recruit Count: 12

Registration Number: NCT05325346

Locations: 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States

Safety and Feasibility of Argatroban as Anticoagulant in Adults With ECMO

Phase 2

Recruiting

Conditions: Anticoagulants and Bleeding Disorders
Extracorporeal Membrane Oxygenation Complication

Interventions: Drug: Argatroban
Drug: Unfractionated heparin

First Posted Date: 2022-02-07

Last Posted Date: 2024-01-17

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 40

Registration Number: NCT05226442

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Not Applicable

Completed

Conditions: Respiratory Failure

Interventions: Drug: unfractionated heparin
Drug: Argatroban

First Posted Date: 2021-06-14

Last Posted Date: 2024-03-26

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 20

Registration Number: NCT04925167

Locations: 🇨🇳
Bing Sun, Beijing, Beijing, China

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Phase 4

Terminated

Conditions: COVID-19

Interventions: Drug: Enoxaparin sodium
Drug: Unfractionated heparin
Drug: Fondapariniux
Drug: Argatroban

First Posted Date: 2020-05-28

Last Posted Date: 2023-09-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 14

Registration Number: NCT04406389

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

Phase 4

Completed

Conditions: Acute Progressive Ischemic Stroke

Interventions: Drug: Argatroban

First Posted Date: 2020-02-19

Last Posted Date: 2023-04-19

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 628

Registration Number: NCT04275180

Locations: 🇨🇳
People's Hospital of Anji, Anji, China
🇨🇳
Min Lou, Hangzhou, Zhejiang, China
🇨🇳
Jiaxing Second Hospital, Jiaxing, China

and more 3 locations

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Phase 3

Terminated

Conditions: Heparin-induced Thrombocytopenia

Interventions: Drug: Danaparoid Sodium
Drug: Argatroban

First Posted Date: 2019-01-18

Last Posted Date: 2022-12-08

Lead Sponsor: Aspen Global Incorporated

Target Recruit Count: 7

Registration Number: NCT03809481

Locations: 🇵🇱
Wojewódzki Szpital Zespolony im. L. Rydygiera, Toruń, Poland
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

and more 32 locations

Argatroban Plus R-tPA for Acute Ischemic Stroke

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: rt-PA
Drug: Argatroban

First Posted Date: 2018-11-14

Last Posted Date: 2022-02-22

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 808

Registration Number: NCT03740958

Locations: 🇨🇳
General Hospital of ShenYang Military Region, ShenYang, China

Multi-arm Optimization of Stroke Thrombolysis

Phase 3

Active, not recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Placebo
Drug: Argatroban
Drug: Eptifibatide

First Posted Date: 2018-11-08

Last Posted Date: 2024-11-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 514

Registration Number: NCT03735979

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 58 locations

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Phase 3

Completed

Conditions: Argatroban
Gynecologic Neoplasms
Low Molecular Weight Heparin
Venous Thromboembolism

Interventions: Drug: LMWH
Drug: s-LMWH
Drug: Argatroban

First Posted Date: 2016-10-17

Last Posted Date: 2019-05-14

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 315

Registration Number: NCT02935530

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy